# Dr.Brain

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dr-brain

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.drbrain.net
- Latest round: Series A (Mar 15, 2021)
- Investors on record: 3

## About

Based in China, Dr.Brain is a diagnostic institution specializing in advanced medical technology solutions, focusing on brain health evaluation through innovative AI-assisted diagnostic tools.Dr.Brain is a medical technology company that provides diagnostics for brain health. Founded in 2017 in Shanghai, China, the company raised a total of CNY 30.000 mn in its Series A funding round on March 15, 2021, with Beijing Beilu Pharmaceutical Co., Ltd as its latest investor. The company has completed 4 deals to date. Silun Wang, the CEO and founder, has been pivotal in steering the company towards its current operational focus.Shenzhen Dr. Brain Technologies Co., Ltd. specializes in advanced medical technology solutions focusing on the evaluation of brain health, primarily through its one-stop multi-modal system for medicine efficacy evaluation. The company's core offerings include AI-assisted diagnostic tools designed for a wide range of CNS diseases, enabling comprehensive analysis of clinical and imaging data. Their flagship services include whole brain examinations, disease risk assessments, brain rehabilitation training, and immersive VR cognitive assessments. The solutions provided serve a diverse client base, including large-scale pharmaceutical companies and primary hospitals, primarily in China, with potential applications in global markets as they expand their reach. These technologies leverage a comprehensive database of Chinese brain imaging supported by state-of-the-art AI algorithms, facilitating high-accuracy diagnosis and treatment planning for various neurological conditions.Shenzhen Dr. Brain Technologies operates a revenue model that revolves around B2B transactions, focusing on partnerships with healthcare institutions, pharmaceutical companies, and research organizations. The company generates revenue through subscriptions for its cloud-based medical imaging platform, which offers services such as intelligent diagnosis and remote consultations. Additionally, revenue is realized from direct sales of proprietary products, including their VR cognitive-motor rehabilitation training system and various imaging analysis services. Specific pricing structures for these products are tailored to client needs, encompassing various service tiers that allow for comprehensive brain health examinations and cognitive assessments. The company’s strategic collaborations further enhance its revenue potential by expanding its service offerings and client engagement in the healthcare sector.Dr.Brain plans to launch new products focused on enhancing their diagnostic capabilities, with specific designs underway to improve the efficiency of their AI tools expected to be released in late 2022. The company aims to expand into international markets, particularly targeting Southeast Asia and Europe by 2023. The CNY 30.000 mn raised in the Series A funding round will support these initiatives by enhancing their product development and marketing strategies.

## Funding rounds

- Series A, Mar 15, 2021 — China Venture Capital
- Angel, Sep 15, 2017 — iResearch Capital, Dalton Venture

## Investors

- iResearch Capital (https://capitalatlas.ai/funds/iresearch-capital) — Angel
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Angel
- China Venture Capital (https://capitalatlas.ai/funds/china-venture-capital) — Series A